Clinical trials: Prostate
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer (Diagnosis)
Virtual Biopsy of Prostate Cancer Using PSMA PET and AI
Prostate cancer is the most common type of cancer in Norwegian men, but many tumors are slow-growing and do not require treatment.
- Trial name
- NCT07266129
- Where
- Norway
- Volunteers
- 220 people
- Sponsor
- University Hospital of North Norway
Prostate Cancer
Pathological Positivity Rate in Prostate Cancer Patients with PI-RADS 4 and First Negative Biopsy
The purpose of this prospective, single-center, single-arm trial was to evaluate the pathologic type of re-treatment based on a clear PI-RADS score of ≥4 with a first negative prostate biopsy, belonging to the high-risk group of…
- Trial name
- NCT06677775
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Hospital
Prostate Cancer
SPCG17: Prostate Cancer Active Surveillance Trigger Trial
A large proportion of men with prostate cancer are overdiagnosed and overtreated mainly due to PSA testing. Active surveillance (AS) aims to reduce these harms by recommending curative treatment only when and if signs of tumor…
- Trial name
- PCASTT (NCT02914873)
- Testing
- Active surveillance
- Where
- 23 sites in Denmark, Finland and 3 more
- Volunteers
- 2,008 people
- Sponsor
- Uppsala University
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Prostate Cancer
C11 Sodium Acetate PET/CT Imaging of PCa
The investigators propose to conduct Carbon-11 Sodium Acetate PET/CT studies. The purpose of our study is to evaluate the impact of Carbon-11 Sodium Acetate PET/CT studies on patient management in patients with prostate cancer.
- Trial name
- NCT02826395
- Testing
- Carbon-11 Sodium Acetate
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
The purpose of this study is to learn about the safety of TALZENNA in patients with BRCA mutation-positive metastatic castration-resistant prostate cancer. BRCA mutation positive means any changes to the BRCA gene.
- Trial name
- NCT06733337
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Benign Prostatic Hypertrophy
Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate
Transurethral therapy (TURiS / PVP) of benign prostatic hyperplasia (BPH) using an ethanol-containing saline irrigating fluid, prospective detected by breath alcohol measurement.
- Trial name
- SATURN-P (NCT02429219)
- Testing
- Saline Irrigation with Ethanol, transurethral resection of the prostate, photoselective vaporisation of the prostate
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Magdeburg
Erectile Dysfunction, Prostate Cancer
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
The purpose of the study is to compare the safety and effectiveness of Prograf in the prevention of erectile dysfunction in men after a radical prostatectomy.
- Trial name
- NCT00106392
- Testing
- Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 131 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00217464
- Testing
- fulvestrant
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Study of a Polymorphism in Patients With Prostate Cancer
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA.
- Trial name
- NCT00900185
- Testing
- mutation analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Tremodi is an observational, non-interventional, prospective, open-label, non-comparative study that will collect real life data of a treatment with Depo-Eligard® in 3 different administrations in male prostate cancer patients.
- Trial name
- TREMODI (NCT01793077)
- Testing
- Depo-Eligard®
- Where
- 23 sites in Belgium
- Volunteers
- 259 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer, Prostate Cancer Stage
Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging
In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with…
- Trial name
- NCT05427864
- Testing
- Multiparametric Prostate MRI
- Where
- Turkey (Türkiye)
- Volunteers
- 47 people
- Sponsor
- Gulhane Training and Research Hospital
Prostate Cancer
Multi-site Decision Impact Study for Decipher
This prospectively designed retrospective clinical utility study will evaluate urologists' treatment recommendations before and after reviewing Decipher results for selected patient cases.
- Trial name
- ASSESS-D (NCT02034825)
- Testing
- Decipher Questionnaire
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- GenomeDx Biosciences Corp
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Prostate Cancer
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1.
- Trial name
- NCT00500110
- Testing
- Docetaxel, Imatinib Mesylate, Leuprolide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Carcinoma
Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial
Purpose of this study is the evaluation of QoL, tolerability and use of Zoladex 10,8 SafeSystem for advanced PCa under naturalistic conditions
- Trial name
- NCT00540059
- Volunteers
- 1,950 people
- Sponsor
- AstraZeneca
Prostate Cancer
Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different way to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic…
- Trial name
- NCT00003238
- Testing
- perillyl alcohol
- Where
- 8 sites in United States
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer, Prostate Cancer Metastatic
18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients
To compare the diagnostic performance of 18-F PSMA PET/CT and CT alone in initial staging, assessment of therapy response, as well as evaluation of biochemical recurrence of prostatic cancer patients The main question it aims to…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
- Trial name
- NCT07485881
- Volunteers
- 59 people
- Sponsor
- Assiut University
Prostate Cancer, Benign Prostatic Hyperplasia
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer.
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Prostatic Intraepithelial Neoplasia
- Trial name
- NCT00400894
- Volunteers
- 750 people
- Sponsor
- ProteoSys AG